Venlectine, 37.5 mg, prolonged-release hard capsules
Venlafaxine
Venlectine is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). Medicines in this group are used to treat depression and other conditions, such as anxiety disorders. It is believed that in people with depression and/or anxiety, the levels of serotonin and norepinephrine in the brain are reduced.
The mechanism of action of antidepressants is not fully understood, but they may help by increasing the levels of serotonin and norepinephrine in the brain.
Venlectine is used to treat depression in adults. It is also indicated for the treatment of the following anxiety disorders in adults: generalized anxiety disorder, social phobia (fear of social situations or avoidance of such situations), and panic disorder (panic attacks). For the patient to feel better, it is essential to follow the treatment correctly. If the treatment is not started, the patient's condition may not improve, and may even worsen, making it more difficult to treat.
Taking irreversible IMAOs with other medicines, including Venlectine, can cause severe or life-threatening side effects. Similarly, before starting to take any IMAO, the patient should wait at least 7 days after stopping Venlectine (see also "Serotonin Syndrome" and "Venlectine and other medicines").
Before starting to take Venlectine, the patient should discuss it with their doctor or pharmacist.
Venlectine may cause feelings of restlessness or an inability to sit or stand still. If such symptoms occur, the patient should inform their doctor.
Medicines like Venlectine (SNRIs) may cause sexual dysfunction (see section 4). In some cases, these symptoms persisted after stopping treatment.
If any of the above applies to the patient, they should consult their doctor before starting to take Venlectine.
The patient should not drink alcohol while taking Venlectine, as it may cause extreme fatigue and loss of consciousness. Taking Venlectine with alcohol and/or certain medicines may increase the severity of depression and other conditions, such as anxiety disorders.
People with depression and/or anxiety disorders may sometimes think about self-harm or suicide. Such symptoms or behavior may worsen when starting to take antidepressants, as these medicines usually start to work after 2 weeks, sometimes later.
The risk of suicidal thoughts is higher if:
If the patient experiences suicidal thoughts or self-harm, they should immediately contact their doctor or go to the emergency room.
It may be helpful to inform family members or friends about the depression or anxiety disorder and ask them to read the leaflet. The patient may ask family members or friends for help and ask them to monitor them if they notice any worsening of depression or anxiety, or any worrying changes in behavior.
Dry mouth
Dry mouth is reported by 10% of patients treated with venlafaxine. It may increase the risk of tooth decay. Therefore, special attention should be paid to oral hygiene.
Venlectine should not be used in children and adolescents under 18 years of age. It should also be noted that patients under 18 years of age who take medicines in this group are at increased risk of side effects, such as suicidal attempts, suicidal thoughts, and hostility (especially aggression, rebellious behavior, and anger). However, the doctor may prescribe Venlectine to patients under 18 years of age if they consider it beneficial for them. If the doctor prescribes Venlectine to a patient under 18 years of age, in case of any doubts, the patient should consult their doctor to discuss it. The doctor should be informed if any of the above symptoms occur or worsen in patients under 18 years of age taking Venlectine. The long-term safety of Venlectine regarding its impact on growth, maturation, and cognitive and behavioral development in this age group has not been established.
The patient should inform their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The doctor will decide whether to use Venlectine with other medicines.
Without consulting the doctor or pharmacist, the patient should not start or stop taking other medicines, including those available without a prescription, herbal medicines, or herbal preparations.
If the patient is taking medicines that may affect heart rhythm, they should tell their doctor.
Examples of such medicines:
The following medicines may also interact with Venlectine, and therefore, should be used with caution. It is particularly important to inform the doctor if the patient is taking medicines containing:
Venlectine should be taken with food (see section 3 "How to take Venlectine").
The patient should not drink alcohol while taking Venlectine. Taking Venlectine with alcohol may cause extreme fatigue and loss of consciousness, as well as worsening of depression and other conditions, such as anxiety disorders.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
Venlectine should only be used after discussing the potential benefits and risks with the doctor.
The patient should ensure that their midwife and/or doctor know that they are taking Venlectine.
Taking Venlectine during pregnancy, like other similar medicines (selective serotonin reuptake inhibitors), may increase the risk of a serious condition called persistent pulmonary hypertension in the newborn, which causes the baby to breathe faster and turn blue. These symptoms usually appear in the first day of life. If the patient notices such symptoms in their baby, they should immediately contact their midwife and/or doctor.
If the patient takes Venlectine during pregnancy, after birth, the baby may experience, in addition to breathing difficulties, other symptoms such as poor feeding. If the patient is concerned about such symptoms in their newborn, they should contact their doctor and/or midwife, who will be able to provide appropriate advice.
Taking Venlectine at the end of pregnancy may increase the risk of severe postpartum hemorrhage, especially if the patient has a history of bleeding disorders. If the patient is taking Venlectine, they should inform their doctor or midwife so that they can provide appropriate advice.
Venlafaxine passes into breast milk and may affect the breastfed baby. However, in babies who have stopped breastfeeding from mothers taking venlafaxine, withdrawal symptoms may occur. Therefore, the patient should discuss this with their doctor, who will decide whether to stop breastfeeding or stop taking Venlectine.
The patient should not drive or operate machinery until they know how the medicine affects them.
The medicine contains less than 1 mmol (23 mg) of sodium per prolonged-release hard capsule, which means it is essentially "sodium-free".
The patient should always take this medicine exactly as their doctor or pharmacist has told them.
In case of doubts, the patient should consult their doctor or pharmacist.
The usual recommended starting dose for depression, generalized anxiety disorder, and social phobia is 75 mg per day. The doctor may gradually increase the dose up to a maximum of 375 mg per day for depression. For panic disorder, treatment should be started with a lower dose (37.5 mg) and then gradually increased. The maximum dose for generalized anxiety disorder, social phobia, and panic disorder is 225 mg per day.
Venlectine should be taken once a day, at approximately the same time, in the morning or evening.
The capsules should be swallowed whole with a small amount of water. They should not be opened, crushed, chewed, or dissolved.
Venlectine should be taken with food.
The patient should inform their doctor about any liver or kidney problems, as a dose adjustment may be necessary.
The patient should not stop taking Venlectine without consulting their doctor (see "Stopping Venlectine").
In case of overdose, the patient should immediately contact their doctor or pharmacist.
Overdose can be life-threatening, especially when taken with alcohol and/or certain medicines (see "Venlectine and other medicines").
Symptoms of possible overdose may include rapid heartbeat, changes in consciousness (from drowsiness to coma), blurred vision, seizures, and vomiting.
If the patient misses a dose, they should take it as soon as possible. However, if it is close to the time for the next dose, they should skip the missed dose and take the next dose at the usual time.
The patient should not take more than the recommended daily dose of Venlectine within a 24-hour period.
The patient should not stop taking Venlectine without consulting their doctor, even if they feel better. If the doctor decides that it is possible to stop taking Venlectine, they will inform the patient how to gradually reduce the dose before completely stopping the treatment.
In patients who stop taking Venlectine, especially after sudden discontinuation or too rapid dose reduction, side effects may occur. Some patients may experience symptoms such as fatigue, dizziness, headache, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, confusion, ringing in the ears, tingling, or (rarely) seizures or flu-like symptoms.
The patient should get information from their doctor on how to gradually stop taking Venlectine. If any of the above symptoms occur or worsen, the patient should consult their doctor.
In case of any further doubts about taking this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Venlectine can cause side effects, although not everybody gets them.
In case of any of the following side effects, the patient should contact their doctor:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Frequency not known (cannot be estimated from the available data):
Venlectine may sometimes cause side effects that the patient may not be aware of, such as increased blood pressure or abnormal heart rhythm; mild changes in sodium, cholesterol, or liver enzyme levels in the blood. In rare cases, Venlectine may weaken the function of platelets, increasing the risk of bruising or bleeding. Therefore, the doctor may recommend regular blood tests, especially during long-term treatment with Venlectine.
If the patient experiences any side effects, including those not listed in the leaflet, they should tell their doctor or pharmacist.
Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, it is possible to gather more information on the safety of the medicine.
The medicine should be stored out of the sight and reach of children.
There are no special precautions for storing the medicinal product.
The patient should not use this medicine after the expiry date stated on the carton after EXP. The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
PVC/PE/PVDC/Aluminum blisters in a cardboard box.
28 or 56 prolonged-release hard capsules (4 or 8 blisters of 7 capsules each).
Bausch Health Ireland Limited
3013 Lake Drive
Citywest Business Campus
Dublin 24, D24PPT3
Ireland
Tel.: +48 17 865 51 00
Bausch Health Poland sp. z o.o.
ul. Przemysłowa 2
35-959 Rzeszów
Pharmathen S.A.
Dervenakion 6, Pallini 15351
Attikis, Greece
Pharmathen International S.A.
Sapes Industrial Park
Block 5
69300 Rodopi, Greece
Bausch Health Poland sp. z o.o.
ul. Kosztowska 21
41-409 Mysłowice
Date of last revision of the leaflet:
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.